Imatinib was the first TKI to be developed to target the BCR-ABL1 protein.8-11 TKIs are particularly effective when CML is treated in the chronic phase (CML-CP). Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.